Elevation in serum troponin I predicts the benefit of tirofiban.
- 1 January 2001
- journal article
- clinical trial
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 11 (3) , 211-215
- https://doi.org/10.1023/a:1011956703031
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive StatusCirculation, 2001
- Coronary microembolizationJournal of the American College of Cardiology, 2000
- Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T LevelsNew England Journal of Medicine, 1999
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Troponin T Identifies Patients With Unstable Coronary Artery Disease Who Benefit From Long-Term Antithrombotic ProtectionJournal of the American College of Cardiology, 1997
- Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1996
- Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial IschemiaNew England Journal of Medicine, 1996
- Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.Circulation, 1985